A Public Participation Forum for the FDA Center for Tobacco Products and its Federal Advisory Committee (TPSAC)

From: Pharmaceutical Processing

MICHAEL FELBERBAUM, AP Tobacco Writer

RICHMOND, Va. (AP) — The public will have more time to weigh in on a federal proposal to regulate electronic cigarettes and other tobacco products.

The Food and Drug Administration said Friday that the public comment period slated to end July 9 is being extended an additional 30 days to Aug. 8 after getting lots of input on how to regulate e-cigarettes. Those are battery-powered devices that heat a liquid nicotine solution, creating vapor that users inhale. The FDA also proposed extending its authority to regulate cigars, hookahs, nicotine gels and pipe tobacco.

From: CSPnet.com

Regulators need to focus on nicotine delivery, acknowledge risk continuum: Zeller

By  Melissa Vonder Haar, Tobacco Editor

WASHINGTON — A comprehensive nicotine policy is one of Mitch Zeller’s top priorities, the director of the U.S. Food & Drug Administration’s Center for Tobacco Products (CTP) said during a Legacy Foundation Warner Series webinar. It was something that was brought up in the preamble to the CTP’s recently released proposed deeming regulations of electronic cigarettes and vaping products.

From: NACS The Association for Convenience and Fuel Retailing

Cost-benefit analysis viewed as radical by some.

NEW YORK – As U.S. health regulators consider what rules to impose on electronic cigarettes, in their tally of costs and benefits they have placed a value on the lost pleasure consumers may suffer if they used the products less or not at all.

According to a report from Reuters, the U.S. Food and Drug Administration says in a little-noticed document released alongside its April proposal for e-cigarette regulation that the projected benefits of the new rules — which also apply to cigars, hookahs and other vapor products — should be cut by 70% to account for the deprivation consumers would suffer.

Editor’s Note: CASAA’s comments highlight a crucial aspect of the FDA’s deeming proprosal, the regulation’s inordinate burden on small American companies.

From: Tobacco Today